Divalproex Sodium NDC 55154-4759

NDC codes

FDA NDC Directory

Product NDC (as listed)55154-4759Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55154-4759Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55154-4759-0	55154475900	10 BLISTER PACK in 1 BAG (55154-4759-0) / 1 CAPSULE, COATED PELLETS in 1 BLISTER PACKMarketed from Mar 18, 2009

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Divalproex Sodium
Generic name (nonproprietary): divalproex sodium
Active ingredients: Divalproex sodium — 125 mg/1
Dosage form: Capsule, Coated pellets
Route: Oral
Labeler: Cardinal Health 107, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078919
Marketing start: Mar 18, 2009
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 55154-4759_87fa431d-7519-4c3d-a390-f2a70f6c2baeSPL ID 87fa431d-7519-4c3d-a390-f2a70f6c2baeSPL set ID 8e86a610-45ef-4be7-a3ab-f656f5b32706RxCUI 1099596UNII 644VL95AO6UPC 0055154475907
Pharmacologic class: Anti-epileptic Agent; Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455154475900 followed by a unit qualifier and the quantity

Package 55154-4759-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1) 1.1 Epilepsy Divalproex sodium delayed-release capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium delayed-release capsules are also indicated for use as sole and adjunctive therapy in the treat…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078919

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078919
Product	Strength	Form · route	Labeler	Product NDC
Divalproex Sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	American Health Packaging	68084-313
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	Zydus Pharmaceuticals USA Inc.	68382-106
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	ATLANTIC BIOLOGICALS CORP.	17856-0109
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	REMEDYREPACK INC.	70518-1749
divalproex sodium	Divalproex sodium 125 mg/1	Capsule, Coated pelletsOral	Zydus Lifesciences Limited	65841-639